Courier Capital LLC Has $387,000 Holdings in Danaher Co. (NYSE:DHR)

Courier Capital LLC cut its stake in shares of Danaher Co. (NYSE:DHR) by 13.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,671 shares of the conglomerate’s stock after selling 254 shares during the period. Courier Capital LLC’s holdings in Danaher were worth $387,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Apella Capital LLC increased its holdings in Danaher by 2.0% in the third quarter. Apella Capital LLC now owns 2,332 shares of the conglomerate’s stock valued at $579,000 after purchasing an additional 46 shares during the period. Nations Financial Group Inc. IA ADV increased its holdings in Danaher by 0.8% in the first quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock valued at $1,779,000 after purchasing an additional 46 shares during the period. Peddock Capital Advisors LLC increased its holdings in Danaher by 0.9% in the third quarter. Peddock Capital Advisors LLC now owns 5,523 shares of the conglomerate’s stock valued at $1,370,000 after purchasing an additional 47 shares during the period. IMS Capital Management increased its holdings in Danaher by 0.4% in the second quarter. IMS Capital Management now owns 11,046 shares of the conglomerate’s stock valued at $2,651,000 after purchasing an additional 49 shares during the period. Finally, New Hampshire Trust increased its holdings in Danaher by 0.3% in the third quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock valued at $3,582,000 after purchasing an additional 50 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Danaher news, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 in the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of NYSE DHR opened at $248.84 on Thursday. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The firm’s 50-day simple moving average is $246.68 and its 200 day simple moving average is $230.40. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The stock has a market cap of $184.07 billion, a price-to-earnings ratio of 38.94, a PEG ratio of 3.77 and a beta of 0.84.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter last year, the firm earned $2.87 EPS. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is currently 15.02%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DHR shares. Royal Bank of Canada increased their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. The Goldman Sachs Group downgraded Danaher from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $215.00 to $205.00 in a report on Thursday, December 7th. Citigroup increased their price target on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, HSBC began coverage on Danaher in a report on Monday, December 18th. They set a “hold” rating for the company. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $266.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.